Stereotaxis (STXS) Stock Price

Stereotaxis Price

NYSE AMEX·CLOSED
1.43USD+0.10 (+7.59 %)
Market closed

Revenue has compounded at 0.9% per year over the past 19 years to 32.38 M USD. Stereotaxis's net margin stands at -66.8%, down from -30.6% several years earlier. Analysts set a median price target of 4.08 USD, implying 184.3% above the current price. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. Over the past year Stereotaxis shares have lost 35.9%. The stock trades about 14% above its 52-week low.

Stereotaxis stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Stereotaxis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Stereotaxis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Stereotaxis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Stereotaxis Stock Price History
DateStereotaxis Price
8/4/20261.43 USD
8/3/20261.33 USD
7/31/20261.26 USD
7/30/20261.33 USD
7/29/20261.34 USD
7/27/20261.34 USD
7/23/20261.41 USD
7/22/20261.49 USD
7/21/20261.47 USD
7/20/20261.50 USD
7/17/20261.55 USD
7/16/20261.65 USD
7/15/20261.62 USD
7/14/20261.60 USD
7/13/20261.64 USD
7/10/20261.70 USD
7/9/20261.74 USD
7/8/20261.80 USD
7/7/20261.82 USD
7/6/20261.79 USD
7/2/20261.79 USD
7/1/20261.77 USD
6/30/20261.72 USD
6/29/20261.73 USD
6/26/20261.68 USD
6/25/20261.62 USD
6/24/20261.63 USD
6/23/20261.75 USD
6/22/20261.88 USD
6/18/20261.88 USD
6/17/20261.78 USD
6/16/20261.82 USD
6/15/20261.84 USD
6/12/20261.84 USD
6/11/20261.82 USD
6/10/20261.85 USD
6/9/20261.85 USD
6/8/20261.81 USD
6/5/20261.78 USD
6/4/20261.88 USD
6/3/20261.84 USD
6/2/20261.97 USD
6/1/20261.94 USD
5/29/20261.98 USD
5/28/20262.08 USD
5/27/20262.01 USD
5/26/20261.95 USD
5/22/20261.92 USD
5/21/20261.90 USD
5/20/20261.85 USD
5/19/20261.73 USD
5/18/20261.78 USD
5/15/20261.85 USD
5/14/20261.94 USD
5/13/20261.85 USD
5/12/20261.92 USD
5/11/20261.88 USD
5/8/20261.90 USD
5/7/20261.90 USD
5/6/20261.92 USD
5/5/20261.92 USD
5/4/20261.90 USD
5/1/20261.93 USD
4/30/20261.87 USD
4/29/20261.82 USD
4/28/20261.86 USD
4/27/20261.93 USD
4/24/20261.93 USD
4/23/20261.98 USD
4/22/20261.94 USD
4/21/20261.92 USD
4/20/20261.98 USD
4/17/20262.03 USD
4/16/20262.01 USD
4/15/20262.01 USD
4/14/20262.03 USD
4/13/20261.92 USD
4/10/20261.87 USD
4/9/20261.95 USD
4/8/20261.93 USD
4/7/20261.85 USD
4/6/20261.88 USD
4/2/20261.87 USD
4/1/20261.85 USD
3/31/20261.84 USD
3/30/20261.78 USD
3/27/20261.82 USD
3/26/20261.89 USD
3/25/20261.86 USD
3/24/20261.80 USD
3/23/20261.84 USD
3/20/20261.79 USD
3/19/20261.82 USD
3/18/20261.80 USD
3/17/20261.89 USD
3/16/20261.91 USD
3/13/20261.89 USD
3/12/20261.88 USD
3/11/20261.93 USD
3/10/20261.97 USD
3/9/20262.07 USD
3/6/20262.05 USD
3/5/20262.19 USD
3/4/20262.20 USD
3/3/20262.14 USD
3/2/20262.22 USD
2/27/20262.16 USD
2/26/20262.21 USD
2/25/20262.20 USD
2/24/20262.10 USD
2/23/20262.14 USD
2/20/20262.07 USD
2/19/20262.08 USD
2/18/20262.03 USD
2/17/20262.08 USD
2/13/20261.99 USD
2/12/20262.02 USD
2/11/20262.03 USD
2/10/20262.10 USD
2/9/20262.12 USD
2/6/20262.03 USD
2/5/20261.98 USD
2/4/20262.09 USD
2/3/20262.18 USD
2/2/20262.21 USD
1/30/20262.19 USD
1/29/20262.33 USD
1/28/20262.49 USD
1/27/20262.53 USD
1/26/20262.59 USD
1/23/20262.67 USD
1/22/20262.73 USD
1/21/20262.75 USD
1/20/20262.64 USD
1/16/20262.68 USD
1/15/20262.79 USD
1/14/20262.75 USD
1/13/20262.68 USD
1/12/20262.56 USD
1/9/20262.51 USD
1/8/20262.58 USD
1/7/20262.60 USD
1/6/20262.55 USD
1/5/20262.36 USD
1/2/20262.32 USD
12/31/20252.30 USD
12/30/20252.29 USD
12/29/20252.30 USD
12/26/20252.46 USD
12/24/20252.43 USD
12/23/20252.45 USD
12/22/20252.45 USD
12/19/20252.34 USD
12/18/20252.32 USD
12/17/20252.32 USD
12/16/20252.38 USD
12/15/20252.32 USD
12/12/20252.37 USD
12/11/20252.42 USD
12/10/20252.37 USD
12/9/20252.38 USD
12/8/20252.36 USD
12/5/20252.41 USD
12/4/20252.43 USD
12/3/20252.33 USD
12/2/20252.25 USD
12/1/20252.34 USD
11/28/20252.46 USD
11/26/20252.43 USD
11/25/20252.47 USD
11/24/20252.36 USD
11/21/20252.32 USD
11/20/20252.24 USD
11/19/20252.24 USD
11/18/20252.29 USD
11/17/20252.12 USD
11/14/20252.22 USD
11/13/20252.24 USD
11/12/20252.43 USD
11/11/20252.85 USD
11/10/20252.79 USD
11/7/20252.72 USD
11/6/20252.68 USD
11/5/20252.81 USD
11/4/20252.70 USD
11/3/20252.78 USD
10/31/20252.91 USD
10/30/20252.92 USD
10/29/20252.92 USD
10/28/20252.97 USD
10/27/20253.05 USD
10/24/20253.09 USD
10/23/20253.10 USD
10/22/20253.04 USD
10/21/20253.05 USD
10/20/20253.10 USD
10/17/20252.99 USD
10/16/20253.03 USD
10/15/20253.15 USD
10/14/20253.05 USD
10/13/20253.07 USD
10/10/20253.07 USD
10/9/20253.37 USD
10/8/20253.57 USD
10/7/20253.18 USD
10/6/20253.30 USD
10/3/20253.14 USD
10/2/20253.04 USD
10/1/20253.14 USD
9/30/20253.11 USD
9/29/20253.06 USD
9/26/20252.94 USD
9/25/20252.92 USD
9/24/20252.93 USD
9/23/20252.93 USD
9/22/20252.88 USD
9/19/20252.81 USD
9/18/20252.80 USD
9/17/20252.76 USD
9/16/20252.79 USD
9/15/20252.82 USD
9/12/20252.85 USD
9/11/20252.88 USD
9/10/20252.81 USD
9/9/20252.89 USD
9/8/20252.88 USD
9/5/20252.90 USD
9/4/20252.76 USD
9/3/20252.71 USD
9/2/20252.71 USD
8/29/20252.88 USD
8/28/20252.81 USD
8/27/20252.87 USD
8/26/20252.78 USD
8/25/20252.76 USD
8/22/20252.88 USD
8/21/20252.84 USD
8/20/20252.85 USD
8/19/20252.88 USD
8/18/20252.78 USD
8/15/20252.73 USD
8/14/20252.90 USD
8/13/20252.70 USD
8/12/20252.66 USD
8/11/20252.54 USD
8/8/20252.50 USD
8/7/20252.19 USD
8/6/20252.25 USD
8/5/20252.24 USD
Access this data via the Eulerpool API
Get Free API Key

Stereotaxis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
26.63 M USD
-6.71 M USD
-6.45 M USD
Jan 1, 2021
35.02 M USD
-12.89 M USD
-10.72 M USD
Jan 1, 2022
28.15 M USD
-18.78 M USD
-19.15 M USD
Jan 1, 2023
26.77 M USD
-21.84 M USD
-20.71 M USD
Jan 1, 2024
26.92 M USD
-24.74 M USD
-24.05 M USD
Jan 1, 2025
32.38 M USD
-22.11 M USD
-21.64 M USD
Jan 1, 2026 (e)
39.40 M USD
-25.93 M USD
-16.40 M USD
Jan 1, 2027 (e)
53.00 M USD
-34.88 M USD
-11.07 M USD

Stereotaxis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 1:07 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
46.0038.0035.0037.0032.0031.0029.0028.0026.0035.0028.0026.0026.0032.0039.0053.00
12.20-17.39-7.895.71-13.51-3.13-6.45-3.45-7.1434.62-20.00-7.14–23.0821.8835.90
67.3971.0574.2972.9775.0064.5279.3178.5769.2365.7164.2953.8553.8553.1353.1353.13
31.0027.0026.0027.0024.0020.0023.0022.0018.0023.0018.0014.0014.0017.0020.7228.16
-10.00-8.00-5.00-5.00-6.00-5.00-2.00-4.00-6.00-12.00-18.00-21.00-24.00-22.00-25.00-34.00
-21.74-21.05-14.29-13.51-18.75-16.13-6.90-14.29-23.08-34.29-64.29-80.77-92.31-68.75-64.10-64.15
-9.00-68.00-5.00-7.00-5.00-5.00–-4.00-6.00-10.00-19.00-20.00-24.00-21.00-16.00-11.00
-71.88655.56-92.6540.00-28.57–––50.0066.6790.005.2620.00-12.50-23.81-31.25
8.3317.2420.6421.5421.8122.8059.0567.9474.9575.8076.3182.7086.8395.9795.9795.97
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Stereotaxis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Stereotaxis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Stereotaxis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Stereotaxis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Stereotaxis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Stereotaxis stock margins

The Stereotaxis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Stereotaxis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Stereotaxis.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
71.22 %
-25.21 %
-24.23 %
Jan 1, 2021
66.34 %
-36.80 %
-30.60 %
Jan 1, 2022
65.62 %
-66.71 %
-68.04 %
Jan 1, 2023
55.51 %
-81.58 %
-77.37 %
Jan 1, 2024
54.22 %
-91.91 %
-89.33 %
Jan 1, 2025
52.73 %
-68.30 %
-66.85 %
Jan 1, 2026 (e)
52.73 %
-65.82 %
-41.62 %
Jan 1, 2027 (e)
52.73 %
-65.82 %
-20.89 %

Stereotaxis Stock Revenue, EBIT, Earnings per Share

The Stereotaxis earnings per share therefore indicates how much revenue Stereotaxis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.36 USD
-0.09 USD
-0.09 USD
Jan 1, 2021
0.46 USD
-0.17 USD
-0.14 USD
Jan 1, 2022
0.37 USD
-0.25 USD
-0.25 USD
Jan 1, 2023
0.32 USD
-0.26 USD
-0.25 USD
Jan 1, 2024
0.31 USD
-0.28 USD
-0.28 USD
Jan 1, 2025
0.34 USD
-0.23 USD
-0.23 USD
Jan 1, 2026 (e)
0.46 USD
-0.27 USD
-0.19 USD
Jan 1, 2027 (e)
0.62 USD
-0.36 USD
-0.13 USD

Stereotaxis business model & stock analysis

Stereotaxis Inc, based in St. Louis, Missouri, is a company that specializes in the development and marketing of advanced instruments and services in magnetic resonance imaging (MRI) and electrophysiology (EP). The company was founded in 1990 and its mission is to improve the accuracy, safety, and efficiency of MRI and EP procedures. The business model of Stereotaxis is based on providing a comprehensive range of systems, instruments, and services to support hospitals and clinics in performing MRI and EP procedures. The company focuses on developing innovative technologies and solutions to improve clinical outcomes and provide the best possible treatment for patients. The company has four main divisions: magnetic resonance imaging (MRI), electrophysiology (EP), cardiovascular diagnostics, and cardiology. In the MRI division, the company offers a variety of instruments and systems specifically designed for MRI procedures. This includes magnetic field control systems, imaging systems, sample collection and analysis instruments, and controls to make MRI procedures more efficient. In the electrophysiology division, Stereotaxis offers instruments and systems that facilitate the navigation and control of medical devices during EP procedures. This includes magnetic field controls and other technologies to improve the accuracy of catheter placement and increase safety during procedures. Stereotaxis's cardiovascular diagnostics division offers various services and technologies that facilitate the performance of cardiology procedures. This includes a comprehensive diagnostic platform that allows for the analysis of heart images. The cardiology division of Stereotaxis offers a comprehensive range of solutions to improve the performance of cardiology procedures in cardiology clinics and hospitals. This includes a range of technologies to improve the diagnosis and treatment of heart diseases. In recent years, Stereotaxis has developed a variety of innovative solutions and technologies to improve the performance of MRI and EP procedures. One example is Robotic Magnetic Navigation, a technology developed by the company to improve the accuracy and safety of EP procedures. This technology allows doctors to improve the navigation and control of catheters during procedures, thereby providing patients with increased treatment safety. Another example is Stereotaxis's Odyssey platform, a solution developed to enable real-time connectivity between various medical devices. This allows doctors to access a variety of information during procedures and make the performance of procedures more efficient. Overall, Stereotaxis has an impressive track record in the development and marketing of advanced solutions and technologies in the MRI and EP industry in recent years. With its innovative technology and comprehensive range of instruments and services, the company is well positioned to continue playing a key role in healthcare in the future.

Stereotaxis SWOT Analysis

Strengths

Stereotaxis Inc is a leading medical technology company specializing in robotic navigation systems.

The company's products offer precise and accurate control during minimally invasive procedures, reducing the risk of complications.

Stereotaxis' technology also allows for improved visualization, enabling physicians to perform complex procedures with greater efficiency.

Weaknesses

Stereotaxis' robotic systems require significant investment, making them expensive for smaller healthcare facilities.

Adoption of the technology may be limited in regions with limited healthcare budgets or outdated infrastructure.

The company heavily relies on research and development, which can result in delays in product launches.

Opportunities

The demand for minimally invasive procedures is growing, creating opportunities for Stereotaxis to expand its market share.

Emerging markets, such as Asia and Latin America, present untapped potential for the adoption of robotic navigation systems in healthcare.

Collaboration with other medical device companies can potentially enhance Stereotaxis' product offerings and increase its competitive advantage.

Threats

Competition from other medical device manufacturers offering similar technologies poses a threat to Stereotaxis' market position.

Changes in healthcare regulations and reimbursement policies can impact the adoption and affordability of Stereotaxis' products.

Technological advancements in alternative treatment options may reduce the demand for Stereotaxis' robotic navigation systems.

Stereotaxis Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Stereotaxis Employees
Details
Date
Stereotaxis Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Stereotaxis Segments

Stereotaxis Revenue by Segment

  • 3 Years

  • 5 Years

  • Max

Disposables Service and Accessories
Disposables, Service and Accessories
Systems
Sublease
Details
Date
Disposables Service and Accessories
Disposables, Service and Accessories
Systems
Sublease
Jan 1, 2018
0.00 USD
27.76 M USD
1.58 M USD
0.00 USD
Jan 1, 2019
0.00 USD
25.85 M USD
2.07 M USD
0.00 USD
Jan 1, 2020
0.00 USD
22.02 M USD
3.63 M USD
0.00 USD
Jan 1, 2021
22.87 M USD
0.00 USD
11.17 M USD
986,120.00 USD
Jan 1, 2022
21.30 M USD
0.00 USD
6.85 M USD
0.00 USD
Jan 1, 2023
18.03 M USD
0.00 USD
8.74 M USD
0.00 USD
Jan 1, 2025
22.15 M USD
0.00 USD
10.22 M USD
0.00 USD

Stereotaxis Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

United States
International
Details
Date
United States
International
Jan 1, 2014
21.63 M USD
13.38 M USD
Jan 1, 2015
19.76 M USD
17.92 M USD

Stereotaxis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Stereotaxis historical P/E ratio, EBIT multiple, and P/S ratio

Stereotaxis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Stereotaxis shares outstanding

The number of shares of Stereotaxis was 95.97 M in 2025. This indicates how many shares Stereotaxis is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
74.95 M Stocks
Jan 1, 2021
75.80 M Stocks
Jan 1, 2022
76.31 M Stocks
Jan 1, 2023
82.70 M Stocks
Jan 1, 2024
86.83 M Stocks
Jan 1, 2025
95.97 M Stocks
Jan 1, 2026 (e)
95.97 M Stocks
Jan 1, 2027 (e)
95.97 M Stocks

Stereotaxis stock splits

In Stereotaxis's history, there have been no stock splits.

Current Stereotaxis forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
90.91 % (10)
Hold
9.09 % (1)
Sell
0.00 % (0)
12M Price Target
4.08
Last Price
1.43
Currency
USD
12M Return Potential
184.32 %
LTM Return
0 %

Stereotaxis Analyst Rating Actions

DateFirmActionRatingReliability
5/13/2026
Piper Sandler
Piper Sandler
MaintainedOverweight51
11/12/2025
Roth Capital
Roth Capital
MaintainedBuy–
3/5/2024
Roth MKM
Roth MKM
MaintainedBuy–
3/5/2024
Lake Street
Lake Street
MaintainedBuy–
3/6/2023
Piper Sandler
Piper Sandler
MaintainedOverweight51
3/6/2023
Lake Street
Lake Street
MaintainedBuy–
3/6/2023
B. Riley Securities
B. Riley Securities
MaintainedBuy–
11/11/2022
Cowen & Co.
Cowen & Co.
MaintainedOutperform60
9/2/2022
B. Riley Securities
B. Riley Securities
MaintainedBuy–
7/12/2022
Aegis Capital
Aegis Capital
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Stereotaxis Earnings Calls

2025

Stereotaxis Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2026-0.05USD-8.52 MUSD-2026 Q2
5/12/2026-0.05USD-8.79 MUSD-2026 Q1
3/9/2026-0.07USD-9.26 MUSD-2025 Q4
11/11/2024-0.05USD-7.24 MUSD-2024 Q3
5/7/2024-0.07USD-6.94 MUSD-2024 Q1
3/1/2024-0.07USD-7.98 MUSD-2023 Q4
11/8/2023-0.05USD-10.28 MUSD-2023 Q3
8/7/2023-0.06USD-9.91 MUSD-2023 Q2
5/8/2023-0.06USD-9.02 MUSD-2023 Q1
11/10/2022-0.06USD-8.32 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Stereotaxis stock

52/100
58
Environment
53
Social
46
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Stereotaxis shareholder structure

% Name
16.33973%
Fischel (Nathan)
Fischel (Nathan)
16.06014%
Dafna Capital Management, LLC
Dafna Capital Management, LLC
5.50331%
Lagoda Investment Management, L.P.
Lagoda Investment Management, L.P.
4.23103%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.87706%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.35025%
Arbiter Partners Capital Management, LLC
Arbiter Partners Capital Management, LLC
...

Stereotaxis Beneficial Ownership Filings (SEC 13D/G)

Free Float
71.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
9.99%
Joe Kiani
Joe Kiani
SEC ↗
9.90%
Jeremy C. Green
Jeremy C. Green
SEC ↗
9.90%
Phil Frohlich
Phil Frohlich
SEC ↗
9.90%
L.L.C.
L.L.C.
SEC ↗
9.90%
II, L.P.
II, L.P.
SEC ↗
9.81%
W. Strauss
W. Strauss
SEC ↗
9.81%
M. Solomon
M. Solomon
SEC ↗
9.81%
B. Stark
B. Stark
SEC ↗
9.70%
Fred A. Middleton
Fred A. Middleton
SEC ↗
9.20%
Robert G. McNeil
Robert G. McNeil
SEC ↗

Stereotaxis Executives and Management Board

8 members · avg. age 61 · 25 % women

KP

Ms. Kimberly Peery (56)

Chief Financial Officer

340,165.00 USD

Management

DF

Mr. David Fischel (38)

Chairman of the Board, Chief Executive Officer · since 2016

62,195.00 USD

Board of Directors

DB

Mr. David Benfer (78)

Lead Independent Director

200,000.00 USD
NF

Dr. Nathan Fischel (69)

Director

200,000.00 USD
MC

Dr. Myriam Curet (68)

Independent Director

200,000.00 USD
RL

Mr. Ross Levin (41)

Independent Director

200,000.00 USD
AM

Dr. Arun Menawat (70)

Independent Director

200,000.00 USD
NS

Mr. Nachum Shamir (71)

Director

90,761.00 USD

Stereotaxis Supply Chain

Stereotaxis Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Johnson & Johnson
Supplier·Customer·Pharmaceuticals·US
0.54
-0.13
-0.69
-0.71
-0.48
0.23

Frequently asked questions about Stereotaxis

Stereotaxis Inc is a leading company in the field of medical technology. The business model of Stereotaxis Inc revolves around providing innovative robotic systems for use in hospitals and medical facilities. These systems assist healthcare professionals in performing minimally invasive procedures, especially in the field of electrophysiology. By combining advanced robotics and precise imaging, Stereotaxis Inc enables physicians to navigate catheters and devices with enhanced accuracy and control. This ultimately improves patient outcomes and reduces the risks associated with traditional surgical methods. With a focus on medical innovation, Stereotaxis Inc continues to revolutionize the healthcare industry through its state-of-the-art robotic technologies.

Stereotaxis Inc is primarily active in the healthcare industry.

The main competitors of Stereotaxis Inc in the market include XYZ Corporation, ABC Corporation, and LMN Corporation.

Stereotaxis Inc is a leading healthcare technology company specializing in robotic surgical systems. Founded in 1990, Stereotaxis has transformed the field of electrophysiology by developing and commercializing innovative robotic platforms. The company's proprietary technology enables physicians to perform precise and minimally invasive procedures, improving patient outcomes. Stereotaxis' versatile robotic systems, including the Niobe® Magnetic Navigation System, have gained recognition for their exceptional precision and safety. With a strong commitment to technological advancements, Stereotaxis Inc continues to revolutionize the medical industry, providing healthcare professionals with cutting-edge tools for improved patient care.

Stereotaxis Inc has achieved several significant milestones since its inception. Notably, the company revolutionized the field of robotic navigation in healthcare by developing the world's first robotic magnetic navigation system. This pioneering technology, known as the Niobe system, enables precise control and navigation of catheters during minimally invasive procedures. Stereotaxis Inc has also successfully expanded its global presence, with installations of the Niobe system in leading hospitals worldwide. Additionally, the company has consistently demonstrated its commitment to innovation, regularly enhancing its platform with advanced features and software updates. These accomplishments have solidified Stereotaxis Inc as a leading player in the field of robotic-assisted healthcare navigation.

Stereotaxis Inc is primarily present in the United States.

Stereotaxis Inc represents values of innovation, precision, and patient-centered care. This medical technology company is committed to revolutionizing the field of surgical robotics, particularly in the area of cardiac care. Their corporate philosophy focuses on enhancing clinical outcomes, reducing procedure time, and improving patient safety through their advanced robotic navigation systems. Stereotaxis Inc aims to provide healthcare professionals with cutting-edge tools that enable minimally invasive procedures and precise, personalized treatments. By harnessing the power of technology and research, Stereotaxis Inc strives to elevate the standard of care for patients worldwide.

Analysts currently set an average price target of 4.28 USD for the Stereotaxis stock (median: 4.08 USD), implying +198.5 % versus the latest price. The consensus is based on 11 analyst ratings.

Stereotaxis Analyst Price Targets 2026

11 analysts currently rate the Stereotaxis stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Stereotaxis to generate revenue of 39.40 M USD and earnings per share of -0.17 USD.

Stereotaxis Analyst Price Targets 2026

Converted at the current exchange rate, the Stereotaxis share trades at 1.25 EUR (1.43 USD).

The Stereotaxis share (STXS) is listed on 3 stock exchanges, including: Frankfurt (RJR1.F), München (RJR1.MU).

The company Stereotaxis Inc has developed an innovative business model that revolutionizes the diagnosis and treatment of heart diseases. The company is a leader in the development of technologies for magnetic catheter treatment, a minimally invasive method for treating heart diseases. Stereotaxis is a global company based in the USA and operates in Europe, Asia, and Australia. The company develops and produces magnetic catheter systems used by cardiologists to treat heart diseases in patients. Stereotaxis' magnetic catheter technology enables precise navigation through the body using an electric magnetic field. The application can be done minimally invasively without surgery. The technology consists of a catheter controlled by a computer. The doctor navigates the catheter using a magnetic field and visualizes the position of the catheter on a screen. Stereotaxis' flagship product is the "Niobe" magnetic catheter system. The system consists of various components, including a computer, a console, a control unit, sensors, catheters, and accessories. The Niobe system has been approved by the US Food and Drug Administration (FDA) and is used by cardiologists worldwide. In addition to selling magnetic catheter systems for the treatment of heart diseases, Stereotaxis also offers services such as the management of magnetic catheter labs. The company provides installation and training services for doctors and medical personnel to ensure effective use of the system. Stereotaxis is not only a hardware provider but also a provider of imaging and diagnostic software. Their "Odyssey" system provides a comprehensive platform for processing patient data and integrating medical devices. Odyssey enables better real-time collaboration among medical personnel and provides opportunities for data analysis. Stereotaxis operates a product focused on data collection and analysis, "Vdrive". Vdrive is a wireless and user-friendly instrument for documenting and recording information during invasive cardiology procedures by medical personnel. It enables the management of patient and procedure data, workflow optimization, and quality management. In addition, Stereotaxis offers a comprehensive fleet of service technicians. Operating globally, it provides 24/7 maintenance and support for the technical equipment in cardiology laboratories. Stereotaxis also has a dedicated marketing department for its customers, which organizes symposia, workshops, and conferences among other activities. Overall, Stereotaxis offers a comprehensive range of products and services for magnetic catheter treatment. With their latest innovations in mixed reality technology and zebra MRI system, the company will continue to conduct groundbreaking research and push the boundaries of medical science.

The expected revenue of Stereotaxis is 39.40 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Stereotaxis is -16.40 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Stereotaxis is currently -8.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Stereotaxis stock.

The price-to-sales ratio (P/S) of Stereotaxis is currently 3.50. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Stereotaxis stock.

The Eulerpool Quality Score for Stereotaxis is 2/10.

The ISIN of Stereotaxis is US85916J4094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Stereotaxis is A1J09L. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Stereotaxis is STXS. The ticker symbol is used to trade Stereotaxis shares on the stock exchange.

Stereotaxis paid dividends every year for the past 0 years.

Stereotaxis is assigned to the 'Health' sector.

The dividends of Stereotaxis are distributed in USD.

All fundamentals and in-depth analysis of Stereotaxis

Our stock analysis for Stereotaxis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stereotaxis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Stereotaxis Stock
Stereotaxis Revenue→
Stereotaxis Stock
Stereotaxis Net Income→
Stereotaxis Stock
Stereotaxis P/E→
Stereotaxis Stock
Stereotaxis P/S→
Stereotaxis Stock
Stereotaxis EBIT→
Stereotaxis Stock
Stereotaxis Dividend→
Stereotaxis Stock
Stereotaxis Directors Dealings→
Stereotaxis Stock
Stereotaxis Stocks→
Stereotaxis Stock
Stereotaxis Market capitalization→
Stereotaxis Stock
Stereotaxis Debt→
Stereotaxis Stock
Stereotaxis Liabilities→
Stereotaxis Stock
Stereotaxis Equity→
Stereotaxis Stock
Stereotaxis AAQS→
Stereotaxis Stock
Stereotaxis Employees→
Stereotaxis Stock
Stereotaxis ROE→
Stereotaxis Stock
Stereotaxis ROA→
Stereotaxis Stock
Stereotaxis ROCE→
Stereotaxis Stock
Stereotaxis News→
Stereotaxis Stock
Stereotaxis Analyst Price Targets→

Health Stocks

STERIS plcStenocare A/SStevanato Group SpAStemRIMStilleStemCell InstituteStimCell EnegeticsStem HoldingsStoke TherapeuticsStem Cells SpinStrata Skin SciencesStella PharmaAll Stocks A–Z →